Muscular dystrophy drug from GlaxoSmithKline, Prosensa fails PhIII

John Carroll GlaxoSmithKline and Prosensa today conceded defeat in the Phase III study for drisapersen, one of two closely-watched therapies for Duchenne muscular dystrophy which had ...

GlaxoSmithKline to supply U.S. with $196M worth of anthrax fighter

Tracy Staton GlaxoSmithKline inked a $ 196 million contract to supply its anthrax remedy, raxibacumab, to the U.S. government FiercePharma News

GlaxoSmithKline whiplashed with bad news, good news for respiratory franchise

Carly Helfand Just after the FDA published draft guidance that would make it easier for generic drugmakers to produce copycat versions of Glaxo's Advair, the agency assembled a ...

Lilly’s warehouse burglar targeted GlaxoSmithKline, too

Tracy Staton A burglar who pulled off a bold warehouse theft at an Eli Lilly facility has now admitted that he made off with millions in GlaxoSmithKline products in a previous heist. FiercePharma ...

FDA experts endorse new COPD blockbuster from GlaxoSmithKline, Theravance

John Carroll GlaxoSmithKline and Theravance have nailed down a solid majority of FDA panel votes in favor of marketing their new COPD therapy Anoro Ellipta. The outside experts voted ...

GlaxoSmithKline near $1.6B drinks-brands sale to Japan’s Suntory

Tracy Staton GlaxoSmithKline may be on the verge of bidding goodbye to two of its drinks brands. Japan's Suntory Beverage & Food is in advanced talks to buy Lucozade and Ribena, ...

GlaxoSmithKline ponders future of Crohn’s disease drug after PhIII flop

John Carroll One of GlaxoSmithKline's late-stage assets for Crohn's disease has failed a Phase III study, pushing the pharma giant to suspend patient recruitment in the ambitious ...

GlaxoSmithKline JV wins FDA OK on HIV blockbuster dolutegravir

John Carroll FierceBiotech News

GlaxoSmithKline wires up $50M VC fund for bioelectronic treatment effort

John Carroll The pharma giant intends to back 5 to 7 drug and device startups in the bioelectronics field over the next 5 years in the latest example of GSK's commitment to come ...

GlaxoSmithKline CEO’s reform-minded rep under fire in China probe

Tracy Staton As the company's current scandal in China shows, Witty was caught somewhat flat-footed by problems there, and some investors wonder whether Witty's reforms have ...

GlaxoSmithKline hits speed bump en route to diabetes drug approval

Tracy Staton The FDA asked for a few more months to review GSK's app on albiglutide, which would compete with Novo Nordisk's Victoza and Bristol-Myers Squibb and AstraZeneca's ...

Moody’s cuts GlaxoSmithKline outlook, citing billions in outlays

Tracy Staton As if GlaxoSmithKline didn't have enough trouble on its hands, Moody's Investors Service has cast some dark clouds over its credit outlook. The agency cut the outlook ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS